- ISIN
- US18978H1023
- CUSIP
- 18978H102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 8, 2019
Highlights
- EPS (TTM)
- -$28.14
- Gross Profit (TTM)
- -$3.88K
- EBITDA (TTM)
- -$13.05M
- Year Range
- $1.90 - $12.84
- Target Price
- $0.50
- ROA (TTM)
- -151.58%
- ROE (TTM)
- -289.02%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CNSP Performance Chart
CNS Pharmaceuticals, Inc. (CNSP) is down 0.2% since the beginning of the year. At $5 per share, CNSP is trading 59.2% below its 52-week high of $13. Investors who bought $1,000 worth of CNSP shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Returns By Period
CNS Pharmaceuticals, Inc. (CNSP) has returned -0.19% so far this year and -56.77% over the past 12 months.
CNS Pharmaceuticals, Inc.
- 1D
- 6.50%
- 1M
- -33.16%
- YTD
- -0.19%
- 6M
- -21.32%
- 1Y
- -56.77%
- 3Y*
- -95.77%
- 5Y*
- -92.23%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
CNSP Monthly Returns History
Based on dividend-adjusted daily data since Nov 8, 2019, CNSP's average daily return is -0.38%, while the average monthly return is -9.42%.
Historically, 26% of months were positive and 74% were negative. The best month was May 2026 with a return of +139.7%, while the worst month was Jun 2024 at -85.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 13 months.
On a daily basis, CNSP closed higher 41% of trading days. The best single day was Apr 14, 2023 with a return of +243.1%, while the worst single day was Jul 30, 2024 at -60.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.29% | -44.27% | -23.15% | -5.02% | 139.65% | -3.68% | -0.19% | ||||||
| 2025 | -21.01% | -48.90% | -44.03% | -20.22% | -5.07% | -19.90% | -19.39% | -22.31% | 45.16% | -14.44% | -9.87% | -24.35% | -92.73% |
| 2024 | -80.47% | 12.10% | 30.22% | -41.62% | 2.29% | -85.38% | -79.95% | -50.38% | -16.98% | -14.48% | 0.36% | 7.50% | -99.81% |
| 2023 | -7.92% | -16.29% | -45.95% | 51.00% | 21.85% | 21.20% | 1.35% | -24.34% | -33.33% | 81.58% | 0.48% | -38.94% | -47.08% |
| 2022 | -14.44% | -35.11% | -12.56% | -0.82% | -10.35% | -7.65% | -21.54% | 11.24% | -26.76% | -10.61% | -36.88% | -20.79% | -88.61% |
| 2021 | -3.37% | 52.91% | -9.13% | -16.32% | -7.50% | 5.95% | -12.24% | -1.16% | -12.35% | -7.38% | -18.84% | -37.29% | -60.54% |
Benchmark Metrics
CNS Pharmaceuticals, Inc. has an annualized alpha of -66.28%, beta of 0.76, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 11, 2019.
- This stock participated in 238.20% of S&P 500 Index downside but only -133.94% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -66.28%
- Beta
- 0.76
- R²
- 0.01
- Upside Capture
- -133.94%
- Downside Capture
- 238.20%
Return for Risk
Risk / Return Rank
CNSP ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for CNS Pharmaceuticals, Inc. (CNSP) and compare them to S&P 500 Index.
| CNSP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.46 | ||
| Sortino ratioReturn per unit of downside risk | -1.91 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.41 | -0.28 |
| Calmar ratioReturn relative to maximum drawdown | -0.68 | 2.93 | -3.61 |
| Martin ratioReturn relative to average drawdown | -1.06 | 13.52 | -14.59 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the CNS Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CNS Pharmaceuticals, Inc. was 100.00%, occurring on Apr 9, 2026. The portfolio has not yet recovered.
The current CNS Pharmaceuticals, Inc. drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -100.00%Apr 2026 | 6y 2mo | — | 6y 4moJan 2020 - now |
2019 correction2019 | -18.38%Dec 2019 | 1mo 9d | 21d | 2moNov 2019 - Jan 2020 |
Drawdown Indicators
| CNSP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -83.25% | -9.10% | -74.15% |
Max Drawdown (3Y)Largest decline over 3 years | -100.00% | -18.90% | -81.10% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -100.00% | -0.74% | -99.26% |
Average DrawdownAverage peak-to-trough decline | -83.44% | -10.72% | -72.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 53.38% | 1.97% | +51.41% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CNS Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CNS Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CNSP
Add CNS Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CNSP